OKYO Pharma Limited
OKYO
$1.61
$0.042.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 126.65% | 126.65% | 10.17% | 10.17% | -72.83% |
| Gross Profit | -126.65% | -126.65% | -10.17% | -10.17% | 72.83% |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.07% | -25.07% | -46.51% | -46.51% | -61.77% |
| Operating Income | 25.07% | 25.07% | 46.51% | 46.51% | 61.77% |
| Income Before Tax | 36.87% | 36.87% | 52.01% | 52.01% | 53.09% |
| Income Tax Expenses | 100.00% | 100.00% | -2,956.29% | -2,956.29% | -1,812.32% |
| Earnings from Continuing Operations | 3.47% | 3.47% | 74.70% | 74.70% | 69.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.47% | 3.47% | 74.70% | 74.70% | 69.61% |
| EBIT | 25.07% | 25.07% | 46.51% | 46.51% | 61.77% |
| EBITDA | 25.06% | 25.06% | 46.51% | 46.51% | 61.78% |
| EPS Basic | 13.28% | 13.28% | 81.63% | 81.63% | 76.73% |
| Normalized Basic EPS | 43.31% | 43.31% | 65.10% | 65.10% | 64.09% |
| EPS Diluted | 13.28% | 13.28% | 81.63% | 81.63% | 76.73% |
| Normalized Diluted EPS | 43.31% | 43.31% | 65.10% | 65.10% | 64.09% |
| Average Basic Shares Outstanding | 11.46% | 11.46% | 37.70% | 37.70% | 30.56% |
| Average Diluted Shares Outstanding | 11.46% | 11.46% | 37.70% | 37.70% | 30.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |